How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
New England Journal of Medicine, alongside Stoke's updated Phase 3 EMPEROR timeline and plans to begin a rolling FDA New Drug Application submission in the first half of 2027. The publication underscored multi-year reductions in seizures and cognitive and behavioral gains in Dravet patients, reinforcing the clinical thesis behind Stoke's antisense platform and raising the importance of the upcoming EMPEROR Phase 3 readout for the company's long-term profile. Next, we'll examine how the NEJM publication and clarified Phase 3 and regulatory timelines could influence Stoke Therapeutics' existing investment narrative. AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. Stoke Therapeutics Investment Narrative Recap To own Stoke Therapeutics, you need to believe zorevunersen can translate its antisense science into a first c
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeBusiness Wire
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics (STOK) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness Wire
- Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.MarketBeat
STOK
Earnings
- 11/4/25 - Miss
STOK
Sec Filings
- 3/4/26 - Form 4
- 3/3/26 - Form 8-K
- 3/2/26 - Form 144
- STOK's page on the SEC website